



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Linzess

Page:

1 of 2

Effective Date: 2/3/2023

Last Review Date: 11/2022

Applies to:	<input checked="" type="checkbox"/> Illinois	<input type="checkbox"/> Florida	<input checked="" type="checkbox"/> Florida Kids
	<input checked="" type="checkbox"/> New Jersey	<input checked="" type="checkbox"/> Maryland	<input type="checkbox"/> Michigan
	<input checked="" type="checkbox"/> Pennsylvania Kids	<input type="checkbox"/> Virginia	

Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for Linzess under the patient's prescription drug benefit.

Description:

Linzess is indicated in adults for the treatment of:

- Irritable bowel syndrome with constipation (IBS-C)
- Chronic idiopathic constipation (CIC)

Applicable Drug List:

Linzess

Policy/Guideline:

The requested drug will be covered with prior authorization when the following criteria are met:

- The requested drug is being prescribed for the treatment of irritable bowel syndrome with constipation (IBS-C) in an adult
 - For a biological female or a person that self-identifies as a female who is 18 years of age or older, a trial and inadequate treatment response to Amitiza or intolerance to Amitiza, or a contraindication to Amitiza is required.

AND

- The patient had treatment failure with one of the following classes: A bulk forming laxative (psyllium, or fiber), or a stimulant laxative (bisacodyl, or senna)

OR

- The requested drug is being prescribed for the treatment of chronic idiopathic constipation (CIC) in an adult

AND

- The patient had treatment failure with one of the following classes: A bulk forming laxative (psyllium, or fiber), or a stimulant laxative (bisacodyl, or senna)



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Linzess

Page:

2 of 2

Effective Date: 2/3/2023

Last Review Date: 11/2022

Applies to:	<input checked="" type="checkbox"/> Illinois	<input type="checkbox"/> Florida	<input checked="" type="checkbox"/> Florida Kids
	<input checked="" type="checkbox"/> New Jersey	<input checked="" type="checkbox"/> Maryland	<input type="checkbox"/> Michigan
	<input checked="" type="checkbox"/> Pennsylvania Kids	<input type="checkbox"/> Virginia	

Approval Duration and Quantity Restrictions:

Approval: 12 months

Quantity Level Limit: Reference Formulary for drug specific quantity level limits

References:

1. Linzess [package insert]. Madison, NJ: Allergan USA, Inc.; April 2021.
2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online, Hudson, Ohio: UpToDate, Inc.; 2021; Accessed July 29, 2021.
3. Micromedex (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Available at: <https://www.micromedexsolutions.com>. Accessed July 29, 2021.